Cargando…

Comparison of amphotericin B deoxycholate in combination with either flucytosine or fluconazole, and voriconazole plus flucytosine for the treatment of HIV-associated cryptococcal meningitis: a prospective multicenter study in China

BACKGROUND: The most appropriate alternative to induction therapy for HIV-associated cryptococcal meningitis (CM) remains unclear when standard treatment is unavailable, inaccessible, intolerable, or ineffective. METHODS: A prospective, multi-centre cohort study was conducted to analyze the data of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Ting, Xu, Xiaolei, Wu, Yushan, Zhang, Wei, Zeng, Qin, Lu, Yanqiu, Yang, Tongtong, Zhou, Guoqiang, Yu, Jianhua, Lan, Ke, Harypursat, Vijay, Chen, Yaokai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358851/ https://www.ncbi.nlm.nih.gov/pubmed/35941618 http://dx.doi.org/10.1186/s12879-022-07665-z

Ejemplares similares

Addition of Flucytosine to Fluconazole for the Treatment of Cryptococcal Meningitis in Africa: A Multicountry Cost-effectiveness Analysis
por: Shiri, Tinevimbo, et al.
Publicado: (2020)

Antifungal Susceptibility to Amphotericin B, Fluconazole, Voriconazole, and Flucytosine in Candida Bloodstream Isolates from 15 Tertiary Hospitals in Korea
por: Jung, Sook-In, et al.
Publicado: (2012)

Short-Course Rather Than Low-Dose Amphotericin B May Exert Potential Influence on Mortality in Cryptococcal Meningitis Patients Treated With Amphotericin B Plus Flucytosine Alone or in Combination With Fluconazole
por: Xu, Lijun, et al.
Publicado: (2019)

Induction therapy with high‐dose fluconazole plus flucytosine for human immunodeficiency virus‐uninfected cryptococcal meningitis patients: Feasible or not?
por: Zhao, Hua‐Zhen, et al.
Publicado: (2022)

Adaptation to Fluconazole via Aneuploidy Enables Cross-Adaptation to Amphotericin B and Flucytosine in Cryptococcus neoformans
por: Yang, Feng, et al.
Publicado: (2021)

Major Role for Amphotericin B–Flucytosine Combination in Severe Cryptococcosis
por: Dromer, Françoise, et al.
Publicado: (2008)

Fluconazole plus flucytosine is a good alternative therapy for non‐HIV and non‐transplant‐associated cryptococcal meningitis: A retrospective cohort study
por: Li, Zhanyi, et al.
Publicado: (2019)

Malassezia pachydermatis fungemia in a preterm neonate resistant to fluconazole and flucytosine
por: Al-Sweih, Noura, et al.
Publicado: (2014)

Flucytosine and Amphotericin B Coadministration Induces Dose-Related Renal Injury
por: Folk, Alexandra, et al.
Publicado: (2017)

Flucytosine and its clinical usage
por: Sigera, L. Shamithra M., et al.
Publicado: (2023)

Evaluation of Hepatotoxicity with Treatment Doses of Flucytosine and Amphotericin B for Invasive Fungal Infections
por: Folk, Alexandra, et al.
Publicado: (2016)

Population pharmacokinetics and CSF penetration of flucytosine in adults with HIV-associated cryptococcal meningoencephalitis
por: Stott, Katharine E, et al.
Publicado: (2023)

Cost-effectiveness analysis of flucytosine as induction therapy in the treatment of cryptococcal meningitis in HIV-infected adults in South Africa
por: Miot, Jacqui, et al.
Publicado: (2021)

Efficacy and Safety of Voriconazole Versus Amphotericin B Deoxycholate Induction Treatment for HIV-Associated Talaromycosis: A Prospective Multicenter Cohort Study in China
por: Zhou, Yihong, et al.
Publicado: (2022)

Vertebral infection with Candida albicans failing caspofungin and fluconazole combination therapy but successfully treated with high dose liposomal amphotericin B and flucytosine
por: Storm, Line, et al.
Publicado: (2014)

Limitation of the Benefit of Amphotericin-Flucytosine Combination Therapy in Patients With Lower Conscious Level: An Ecological Fallacy?
por: Wolbers, Marcel, et al.
Publicado: (2015)

An Elderly Patient with Pulmonary Cryptococcosis with Mediastinal Lymphadenopathy Who Was Successfully Treated with Amphotericin B and Flucytosine
por: Fujimoto, Shusaku, et al.
Publicado: (2020)

Carbon Dioxide Potentiates Flucytosine Susceptibility in Cryptococcus neoformans
por: Jezewski, Andrew J., et al.
Publicado: (2023)

The silent flucytosine shortage in Europe – not a distant problem
por: Sprute, Rosanne, et al.
Publicado: (2023)

P092 Otilonium bromide is a potent antifungal agent against fluconazole- and flucytosine-resistant Cryptococcus neoformans strains
por: Zhen, Cheng, et al.
Publicado: (2022)

161. Flucytosine Utilization and Dosing Practices at an Academic Medical Center
por: Miller, Molly M, et al.
Publicado: (2021)

Toxicity of Amphotericin B Deoxycholate-Based Induction Therapy in Patients with HIV-Associated Cryptococcal Meningitis
por: Bicanic, Tihana, et al.
Publicado: (2015)

Liposomal flucytosine capped with gold nanoparticle formulations for improved ocular delivery
por: Salem, Heba F, et al.
Publicado: (2016)

Prediction and experimental validation of solid solutions and isopolymorphs of cytosine/5-flucytosine†
por: Braun, D. E., et al.
Publicado: (2017)

Factors Influencing the Nitrogen-Source Dependent Flucytosine Resistance in Cryptococcus Species
por: Yang, Dong-Hoon, et al.
Publicado: (2023)

Population Pharmacokinetic Model and Meta-analysis of Outcomes of Amphotericin B Deoxycholate Use in Adults with Cryptococcal Meningitis
por: Stott, Katharine E., et al.
Publicado: (2018)

Flucytosine for treatment of Candida albicans in H1N1-positive patient
por: Samra, Tanvir, et al.
Publicado: (2010)

A randomized open label trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis.
por: Ngan, Nguyen Thi Thuy, et al.
Publicado: (2019)

An open label randomized controlled trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis
por: Ngan, Nguyen Thi Thuy, et al.
Publicado: (2021)

829. 5-Flucytosine Longitudinal Antifungal Susceptibility Testing of Cryptococcus neoformans: A Sub-study of the EnACT Trial Testing Oral Amphotericin
por: McHale, Thomas, et al.
Publicado: (2023)

Severe anemia, severe leukopenia, and severe thrombocytopenia of amphotericin B deoxycholate-based induction therapy in patients with HIV-associated talaromycosis: a subgroup analysis of a prospective multicenter cohort study
por: Zhou, Yihong, et al.
Publicado: (2023)

Clonal Population of Flucytosine-Resistant Candida tropicalis from Blood Cultures, Paris, France
por: Desnos-Ollivier, Marie, et al.
Publicado: (2008)

New Mechanisms of Flucytosine Resistance in C. glabrata Unveiled by a Chemogenomics Analysis in S. cerevisiae
por: Costa, Catarina, et al.
Publicado: (2015)

Flucytosine Pharmacokinetics in a Critically Ill Patient Receiving Continuous Renal Replacement Therapy
por: Kunka, Megan E., et al.
Publicado: (2015)

Prevalence and Hospital Management of Amphotericin B Deoxycholate-Related Toxicities during Treatment of HIV-Associated Cryptococcal Meningitis in South Africa
por: Meiring, Susan, et al.
Publicado: (2016)

Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal
por: Loyse, Angela, et al.
Publicado: (2013)

Effective Voriconazole in an Immunocompetent Patient With Amphotericin B Resistant Systemic Cryptococcal Granulomatosis
por: Serraj, Khalid, et al.
Publicado: (2020)

Sequential Photodynamic Therapy with Phthalocyanine Encapsulated Chitosan-Tripolyphosphate Nanoparticles and Flucytosine Treatment against Candida tropicalis
por: Hsieh, Yi-Hsuan, et al.
Publicado: (2019)

1331. High direct costs caused by Cryptococcal meningitis treated with Amphotericin B deoxycholate in a public hospital in Lima, Peru. 2021-2022
por: Vilcarromero, Stalin, et al.
Publicado: (2023)

Emerging fluconazole resistance: Implications for the management of cryptococcal meningitis
por: Mpoza, Edward, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ie14dgusrgso2jl7t4kaog5i3i